Pharma Focus Europe

Myricx Bio and Wuxi Biologics Establish Exclusive Agreement for Antibody Licensing

Wednesday, November 22, 2023

Myricx Bio, a UK-based biotech firm focused on discovering and developing a new class of antibody-drug conjugate (ADC) payloads centered on N-Myristoyltransferase inhibition (NMTi), has announced a licensing agreement with WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO).

As per the terms of the agreement, Myricx gains exclusive access to a proprietary antibody discovered through WuXi Bio's integrated technology platforms. Myricx plans to use this antibody to develop a first-in-class ADC, leveraging its NMTi payload platform, known for its distinct advantages over conventional payload classes such as microtubule and topoisomerase inhibitors. The goal is to advance the ADC through preclinical and clinical stages for challenging-to-treat solid tumors.

WuXi Bio will receive an upfront payment and stand to benefit from development and commercialization milestone payments, along with royalties based on net sales. NMT is a crucial enzyme that adds a specific lipid modification to various protein targets essential for the survival of cancer cells.

Myricx has recently demonstrated the effectiveness of its NMTi payload platform across multiple tumor-associated antigens, including B7-H3, TROP2, and HER2, earning recognition with the Best Poster award at the 14th Annual World ADC conference in San Diego. This agreement marks the second antibody license deal for Myricx in the past few months, reinforcing the company's commitment to expanding its pipeline of NMTi-ADCs.

Myricx, expressed delight at the agreement with WuXi Bio, highlighting the potential for significant clinical differentiation in solid tumors by combining the leading antibody with Myricx's novel NMTi-based payload. Dr. Chris Chen, CEO of WuXi Biologics, emphasized the agreement as a testament to their integrated platform's capabilities, showcasing their commitment to fostering the development of innovative biologics for the global benefit of patients.

Myricx, a spin-out from Imperial College London and the Francis Crick Institute, has its roots in the unique insights into NMT biology provided by its founders, Professors Ed Tate and Roberto Solari. The company received seed financing from Sofinnova Partners and Brandon Capital.

 

Source: globenewswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva